Casdatifan + Cabozantinib for Kidney Cancer

This trial tests a new combination of treatments for advanced kidney cancer that has continued to grow despite previous treatment. It compares the effects of casdatifan (a new potential drug) plus cabozantinib against a placebo (a substance with no treatment effect) plus cabozantinib to determine which combination better stops cancer progression. People with advanced kidney cancer of the clear cell type who have already tried certain cancer treatments may be suitable candidates. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that the combination of casdatifan and cabozantinib is generally well-tolerated by patients with clear cell renal cell carcinoma, a type of kidney cancer. Studies indicate that nearly half of the patients responded positively to this treatment. Importantly, the side effects remain manageable. Most side effects, such as anemia (fewer red blood cells than normal), did not require a change in dosage. Overall, this suggests that the treatment is fairly safe for most patients.¹²³⁴⁵

Researchers are excited about Casdatifan because it offers a fresh approach to treating kidney cancer. Unlike current treatments that typically focus on targeting cancer growth pathways, Casdatifan works differently by inhibiting a specific protein that plays a crucial role in cancer cell survival. This unique mechanism could potentially make it more effective in stopping cancer progression compared to existing options. Additionally, when combined with cabozantinib, a drug that already targets multiple pathways in kidney cancer, Casdatifan may enhance overall treatment effectiveness, providing hope for better outcomes.

In this trial, participants in the experimental arm will receive a combination of casdatifan and cabozantinib. Research has shown that nearly half of the patients with advanced kidney cancer responded well to this combination. Specifically, about 4% of these patients experienced a complete disappearance of their cancer, while 42% saw a significant reduction in its size. This combination treatment has an overall response rate of 46%, indicating that nearly half of the patients had a positive outcome. These results are encouraging, particularly for those who have already tried other treatments. Additionally, the side effects were manageable, which is important for ongoing treatment.¹²⁴⁶⁷